HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evodiamine inhibits both stem cell and non-stem-cell populations in human cancer cells by targeting heat shock protein 70.

Abstract
Rationale: Cancer stem cells (CSCs) are known to cause tumor recurrence and drug resistance. The heat shock protein (HSP) system plays a major role in preserving expression and function of numerous oncoproteins, including those involved in the CSC activities. We explored novel anticancer drugs, especially those targeting HSP components required for the functional role of CSCs. Methods: Investigation of the role of the HSP system in CSCs and screening of a natural product chemical library were performed by utilizing cancer cell lines, primary cultures of patient-derived xenografts (PDXs), and their putative CSC subpopulations (i.e., those grown under sphere-forming conditions, stably transfected with reporter vectors carrying NANOG or POUSF1 promoters, or carrying high ALDH activity) in vitro and PDX and KrasG12D/+-driven tumor models in vivo. Regulation of the HSP system was investigated by immunoprecipitation, drug affinity responsive target stability assay, binding experiments using ATP-agarose beads and biotinylated drug, and docking analysis. Results: The HSP system was activated in CSCs via transcriptional upregulation of the HSP system components, especially HSP70. Evodiamine (Evo) was identified to induce apoptosis in both CSC and bulk non-CSC populations in human lung, colon, and breast cancer cells and their sublines with chemoresistance. Evo administration decreased the multiplicity, volume, and load of lung tumors in KrasG12D/+ transgenic mice and the growth of cancer cell line- and PDX-derived tumors without detectable toxicity. Mechanistically, Evo disrupted the HSP system by binding the N-terminal ATP-binding pocket of HSP70 and causing its ubiquitin-mediated degradation. Conclusions: Our findings illustrate HSP70 as a potential target for eliminating CSCs and Evo as an effective HSP70-targeting anticancer drug eradicating both CSCs and non-CSCs with a minimal toxicity.
AuthorsSeung Yeob Hyun, Huong Thuy Le, Hye-Young Min, Honglan Pei, Yijae Lim, Injae Song, Yen T K Nguyen, Suckchang Hong, Byung Woo Han, Ho-Young Lee
JournalTheranostics (Theranostics) Vol. 11 Issue 6 Pg. 2932-2952 ( 2021) ISSN: 1838-7640 [Electronic] Australia
PMID33456581 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© The author(s).
Chemical References
  • Antineoplastic Agents
  • HSP70 Heat-Shock Proteins
  • Quinazolines
  • evodiamine
Topics
  • A549 Cells
  • Animals
  • Antineoplastic Agents (pharmacology)
  • Apoptosis (drug effects)
  • Cell Line
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • HCT116 Cells
  • HSP70 Heat-Shock Proteins (metabolism)
  • Humans
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Mice, Transgenic
  • Neoplasms (drug therapy, metabolism)
  • Neoplastic Stem Cells (drug effects, metabolism)
  • Quinazolines (pharmacology)
  • Signal Transduction (drug effects)
  • Transcription, Genetic (drug effects)
  • Up-Regulation (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: